Premium
L‐norgestrel and progesterone have different influences on plasma lipoproteins
Author(s) -
FÅHRAEUS LARS,
LARSSONCOHN ULF,
WALLENTIN LARS
Publication year - 1983
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1983.tb00127.x
Subject(s) - norgestrel , endocrinology , medicine , progestin , cholesterol , levonorgestrel , chemistry , very low density lipoprotein , lipoprotein , hormone , population , research methodology , environmental health , family planning
. Twenty‐six postmenopausal women wh had been on cutaneous oestradiol treatment for 3–6 months were given either 120 μg of l‐norgestrel ( n = 13) or 300 mg of progesterone ( n = 13) sequentially fc another 6 months. The concentrations of cholestero phospholipids and triglycerides were determined i plasma and in the HDL, HDL 2 , HDL 3 , LDL an VLDL fractions before and after one, three and si cycles of progestin treatment. Already after 11 days on l‐norgestrel, the mea HDL cholesterol and the mean HDL phospholipi concentrations were reduced by 15%. The reduction c the HDL‐lipids was mainly confined to the HDL fraction which was decreased by 25–30%. L‐norgestn also reduced the mean TG concentration both in the VLDL and the combined LDL + HDL fraction Progesterone gave only minor changes of the plasm lipids and lipoproteins. Reduced HDL, especially HDL 2 , concentration, a induced by l‐norgestrel, might increase the risk fc ischaemic heart disease. Therefore, it seems that, a regards the effects on the lipoproteins, progesteron might be more suitable than the 19‐nortestosteron derivated l‐norgestrel for postmenopausal sequenti; hormonal therapy.